Chabner Ba
About
In The Last Decade
Chabner Ba
20 papers receiving 420 citations
Peers
Comparison fields: 5 of 76
- Oncology 238
- Pathology and Forensic Medicine 167
- Molecular Biology 132
- Genetics 72
- Pulmonary and Respiratory Medicine 56
Countries citing papers authored by Chabner Ba
This map shows the geographic impact of Chabner Ba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chabner Ba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chabner Ba more than expected).
Fields of papers citing papers by Chabner Ba
This network shows the impact of papers produced by Chabner Ba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chabner Ba. The network helps show where Chabner Ba may publish in the future.
Co-authorship network of co-authors of Chabner Ba
This figure shows the co-authorship network connecting the top 25 collaborators of Chabner Ba. A scholar is included among the top collaborators of Chabner Ba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chabner Ba. Chabner Ba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Drug resistance in adult lymphomas. | 12 |
| 2 | Antifolate metabolism and sites of action: implications for the design of new antifolates. | 2 |
| 3 | The lymphomas: biologic implications of therapy and therapeutic implications of the new biology. | 4 |
| 4 | National Institutes of Health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. Editorial overview. | 7 |
| 5 | Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. | 9 |
| 6 | Competitive protein-binding assay for trimetrexate. | 7 |
| 7 | Surgical oncology research development: the perspective of the National Cancer Institute. | 3 |
| 8 | Drug resistance in cancer. | 137 |
| 9 | Symposium on cellular resistance to anticancer drugs. Introduction. | 7 |
| 10 | Clinical pharmacology of methotrexate. | 34 |
| 11 | The role of target determinants in antineoplastic therapy. | 0 |
| 12 | Staging of non-Hodgkin's lymphoma. | 30 |
| 13 | Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. | 2 |
| 14 | Sequential staging in non-Hodgkin's lymphoma. | 34 |
| 15 | Allergic reaction to cyclophosphamide in a mechlorethamine-sensitive patient. | 12 |
| 16 | Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. | 88 |
| 17 | Clinical pharmacology of anticancer drugs. | 73 |
| 18 | Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. | 13 |
| 19 | High-dose intermittent intravenous infusion of procarbazine (NSC-77213). | 7 |
| 20 | Proceedings: Malignant lymphoma: treatment with combination chemotherapy. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.